TREA

79069161

Follow

Information

  • Trademark
  • 79069161
  • Serial Number
    79069161
  • Registration Number
    3771814
  • Filing Date
    February 14, 2008
    17 years ago
  • Registration Date
    April 06, 2010
    14 years ago
  • Transaction Date
    September 01, 2018
    6 years ago
  • Status Date
    February 15, 2018
    7 years ago
  • Published for Opposition Date
    January 19, 2010
    15 years ago
  • Location Date
    January 06, 2010
    15 years ago
Information
Mark Drawing Code
2000
Case File Statements
  • CC0000: Color is not claimed as a feature of the mark.
  • DM0000: The mark consists of an oval inside of which appears a stick figure shape formed from a circle above a rectangle with rounded edges and which dissects an oval shape. The transliteration of the non-Latin characters, which appear below the design, is "YI LING", which are the Chinese characters constituting the first name of the president of the applicant. The two characters as so combined do not have any meaning in English.
  • GS0051: Pharmaceutical preparations for the treatment of cardiovascular system diseases, namely, hypertension, and heart failure; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of nutrition metabolism barrier diseases, namely, malnutrition and beriberi; Pharmaceutical preparations for the treatment of metabolism diseases, namely, diabetes, obesity, diabetic ketoacidosis, hypoxemia DKA and high fat proteinemia; Pharmaceutical preparations for the treatment of endocrine system diseases, namely, next cerebral ganglion pituitary gland sickness, thyroid gland sickness, ophoropathy and parathyroid sickness; Pharmaceutical preparations for the treatment of circulatory system diseases, namely, shock, heart valve sickness, arrhythmia, arteriosclerosis, cardiomyopathy periphery blood vessel disease, hypertensive disease and pericarditis; Pharmaceutical preparations for the treatment of respiratory disorder, namely, chronic bronchitis, bronchial asthma, disease of pulmonary circulation, pneumonia and acute trachea bronchitis; Pharmaceutical preparations for the treatment of digesting system diseases, namely, abdominal pain, constipation, diarrhea, cholecystitus, liver cirrhosis, liver function failure and gastritis; Pharmaceutical preparations for the treatment of urinary system diseases, namely, kidney stone, renal tumor, chronic kidney function failure, urinary tract infection and cystonephrosis; Pharmaceutical preparations for the treatment of hematopoietic system diseases, namely, anemia, leukemia and lymphoma; Pharmaceutical preparations for the treatment of immune system diseases, namely, serum sickness, allergic shock and allergic rhinitis; Pharmaceutical preparations for the treatment of rheumatic diseases and osteoarthritis, namely, rheumatic fever, lupus erythematosus, sjogren's syndrome, behcet disease and dermatomyositis; Pharmaceutical preparations for the treatment of nerve diseases, namely, schizophrenia and neurosis; Pharmaceutical preparations for the treatment of nervous system diseases, namely, headache, multiple sclerosis and muscle diseases; Pharmaceutical preparations for the treatment of skin diseases, namely, eczema, belt-shaped blister measles, namely, herpes zoster, connective tissue disease, lupus erythematosus and nervous dermatitis; Pharmaceutical preparations for the treatment of reproductive system inflammation, namely, pelvic inflammatory disease, cervicitis and vestibule big gland inflammation; Pharmaceutical preparations for the treatment of natural dissemination diseases, namely, gonorrhea, syphilis and AIDS; Pharmaceutical preparations for the treatment of female reproductive system tumor, namely, sarcoma uteri, carcinoma of cervix and endometrium cancer; Pharmaceutical preparations for the treatment of menopathy, namely, menopause, painful menstruation and menopause syndrome; Pharmaceutical preparations for the treatment of newborn symptom and diseases, namely, the newborn faints from fright, newborn vomit and newborn septicaemia; Pharmaceutical preparations for the treatment of surgical department conditions, namely, tetanus, wounds and tumors
  • TLIT00: The non-Latin characters in the mark transliterate to "YI LING" and this has no meaning in a foreign language.
  • TR0010: The wording "YI LING" has no meaning in a foreign language.
Case File Event Statements
  • 8/31/2018 - 6 years ago
    38 - NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED Type: DENC
  • 8/31/2018 - 6 years ago
    37 - DEATH OF INTERNATIONAL REGISTRATION Type: DETH
  • 1/11/2018 - 7 years ago
    36 - CHANGE OF NAME/ADDRESS REC'D FROM IB Type: ADCH
  • 8/4/2017 - 7 years ago
    35 - TOTAL INVALIDATION PROCESSED BY THE IB Type: INNT
  • 7/13/2017 - 7 years ago
    34 - GENERIC MADRID TRANSACTION SENT TO IB Type: XXSS
  • 7/13/2017 - 7 years ago
    33 - GENERIC MADRID TRANSACTION CREATED Type: XXCR
  • 7/11/2017 - 7 years ago
    32 - TOTAL INVALIDATION OF REG EXT PROTECTION CREATED Type: INTR
  • 11/11/2016 - 8 years ago
    31 - CANCELLED SECTION 71 Type: C71T
  • 3/25/2016 - 8 years ago
    30 - TEAS CHANGE OF CORRESPONDENCE RECEIVED Type: TCCA
  • 2/7/2013 - 12 years ago
    29 - FINAL DECISION TRANSACTION PROCESSED BY IB Type: FINO
  • 7/28/2010 - 14 years ago
    28 - FINAL DISPOSITION NOTICE SENT TO IB Type: FICS
  • 7/28/2010 - 14 years ago
    27 - FINAL DISPOSITION PROCESSED Type: FIMP
  • 7/7/2010 - 14 years ago
    26 - FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB Type: FICR
  • 4/6/2010 - 14 years ago
    25 - REGISTERED-PRINCIPAL REGISTER Type: R.PR
  • 1/19/2010 - 15 years ago
    24 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 1/19/2010 - 15 years ago
    23 - PUBLISHED FOR OPPOSITION Type: PUBO
  • 12/14/2009 - 15 years ago
    22 - LAW OFFICE PUBLICATION REVIEW COMPLETED Type: PREV
  • 12/8/2009 - 15 years ago
    21 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 12/8/2009 - 15 years ago
    20 - EXAMINER'S AMENDMENT ENTERED Type: XAEC
  • 12/8/2009 - 15 years ago
    19 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Type: GNEN
  • 12/8/2009 - 15 years ago
    18 - EXAMINERS AMENDMENT E-MAILED Type: GNEA
  • 12/8/2009 - 15 years ago
    17 - EXAMINERS AMENDMENT -WRITTEN Type: CNEA
  • 11/20/2009 - 15 years ago
    16 - CORRECTION TRANSACTION RECEIVED FROM IB Type: CRCV
  • 11/18/2009 - 15 years ago
    15 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 11/18/2009 - 15 years ago
    14 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 11/18/2009 - 15 years ago
    13 - ASSIGNED TO LIE Type: ALIE
  • 11/5/2009 - 15 years ago
    12 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 11/5/2009 - 15 years ago
    11 - ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Type: ARAA
  • 11/5/2009 - 15 years ago
    10 - TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Type: REAP
  • 7/24/2009 - 15 years ago
    9 - REFUSAL PROCESSED BY IB Type: RFNT
  • 6/30/2009 - 15 years ago
    8 - NON-FINAL ACTION MAILED - REFUSAL SENT TO IB Type: RFCS
  • 6/30/2009 - 15 years ago
    7 - REFUSAL PROCESSED BY MPU Type: RFRR
  • 6/30/2009 - 15 years ago
    6 - NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW Type: RFCR
  • 6/30/2009 - 15 years ago
    5 - APPLICATION FILING RECEIPT MAILED Type: MAFR
  • 6/29/2009 - 15 years ago
    4 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 6/26/2009 - 15 years ago
    3 - ASSIGNED TO EXAMINER Type: DOCK
  • 6/26/2009 - 15 years ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM Type: NWOS
  • 6/25/2009 - 15 years ago
    1 - SN ASSIGNED FOR SECT 66A APPL FROM IB Type: REPR